Revolution Medicines, Inc. RVMD
172.29 USD -4.06 (-2.30%)
Regular-session close
169.91 -2.38 -1.38%
After hours · Nov 13, 6:15 PM ET
168.62 Day range 176.06
64.38 52-week range 221.15
- YTD
- +116.31%
- 1 year
- +167.61%
News
benzinga.com Morgan Stanley Maintains Overweight on Revolution Medicines, Lowers Price Target to $247 Morgan Stanley analyst Sean Laaman maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target from $272 to $247.
defenseworld.net Chicago Partners Investment Group LLC Acquires New Position in Revolution Medicines, Inc. $RVMD Chicago Partners Investment Group LLC acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to its most recent 13F filing with the…
defenseworld.net Revolution Medicines, Inc. $RVMD Shares Sold by Alphabet Inc. Alphabet Inc. trimmed its stake in Revolution Medicines, Inc. (NASDAQ: RVMD) by 9.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 2,673,909 shares of…
benzinga.com FDA Reportedly Shelves Fast-Track Drug Review Pilot Program During Leadership Vacuum: Report The FDA reportedly shelves its fast-track drug voucher pilot amid internal chaos, returning review oversight to career scientists.
benzinga.com Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 30.9% on an annualized basis producing an average annual return of 41.09%. Currently, Revolution Medicines has…
seekingalpha.com Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High Revolution Medicines has transitioned to commercial operations with a strong initial RASONQUE launch, generating $197.6M in five weeks post-FDA approval. RASONQUE's early demand is validated by over…
benzinga.com Nasdaq 100 Jumps 2.8% as CoreWeave, Nvidia Climb: Stock Market Today CoreWeave's 25.1% surge revived the AI trade, lifting chipmakers, memory and power stocks, while Nvidia shrugged off a Baird downgrade.
defenseworld.net Revolution Medicines (NASDAQ:RVMD) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Survey Krystal Biotech (NASDAQ: KRYS - Get Free Report) and Revolution Medicines (NASDAQ: RVMD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two…
seekingalpha.com Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Revolution Medicines, Inc. ( RVMD ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 8:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Presentation…
zacks.com Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet The consensus price target hints at a 33.3% upside potential for Revolution Medicines (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…
fool.com Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy? Its lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer. The young drug company has a revolutionary pipeline of RAS-inhibitor therapies.
fool.com Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug Revolution Medicines' daraxonrasib has received FDA approval. Royalty Pharma estimates that the drug could produce peak revenues of $11 billion.
benzinga.com HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $350 HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $280 to $350.
benzinga.com TD Cowen Maintains Buy on Revolution Medicines, Raises Price Target to $270 TD Cowen analyst Tyler Van Buren maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $250 to $270.
benzinga.com RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $321 RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $260 to $321.
benzinga.com Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $222 Piper Sandler analyst Kelsey Goodwin maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $210 to $222.
benzinga.com Truist Securities Reiterates Buy on Revolution Medicines, Raises Price Target to $261 Truist Securities analyst Gregory Renza reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $241 to $261.- benzinga.com Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $298 Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $275 to $298.
- benzinga.com Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $340 Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $320 to $340.
benzinga.com Revolution Medicines Q3 2026 Earnings Call Transcript Revolution Medicines (NASDAQ:RVMD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…- benzinga.com Revolution Medicines Q3 EPS $(1.90) Beats $(2.42) Estimate, Sales $197.559M May Not Be Comparable To $23.495M Estimate Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(2.42) by 21.49 percent. This is a 18.01 percent decrease over losses…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
benzinga.com Jim Cramer: This Tech Stock ‘Sells At A Low Multiple’ Jim Cramer favors Penguin Solutions for its low valuation after strong earnings and says investors should let Revolution Medicines run.
benzinga.com Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.
benzinga.com Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.96% on an annualized basis producing an average annual return of 46.71%. Currently, Revolution Medicines has…- benzinga.com Revolution Medicines Presents Exploratory Subgroup Analyses From Phase 3 RASolute 302 Trial, As Late-Breaking Abstract At ESMO Congress 2026 Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival…
- benzinga.com Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today…
benzinga.com TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target TD Cowen analyst Tyler Van Buren reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $250 price target.
benzinga.com Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment Revolution Medicines doses first patients in its global Phase 3 trial testing zoldonrasib for metastatic non-small cell lung cancer.- benzinga.com Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241 Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $241.
benzinga.com Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow William Blair sets $226 price target for Revolution Medicines (RVMD) following Rasonque approval and major oncology expansion plans.- benzinga.com William Blair Initiates Coverage On Revolution Medicines with Outperform Rating William Blair analyst Alethia Young initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating.
- benzinga.com Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $275 price target.